<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00442169</url>
  </required_header>
  <id_info>
    <org_study_id>H-244-003</org_study_id>
    <nct_id>NCT00442169</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults</brief_title>
  <official_title>Randomized, Double-blind, Placebo Controlled Phase II Trial of the Safety, Tolerability and Immunogenicity of Lyophilized ChimeriVax-WN02 West Nile Vaccine in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a single subcutaneous injection of
      ChimeriVax-WN02 vaccine is well tolerated, safe and induces protective antibodies against
      West Nile Disease. The study is divided into two parts; in the first part, a comparison of 3
      dose levels of the vaccine will be made, with an inactive control. In the second part, the
      optimum dose level chosen after the first part will be given to older volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      West Nile Disease has been carried across the United States by migrating birds since it was
      first identified in New York city in 1999. It is transmitted by mosquitoes from birds to
      humans and can cause severe disease in some individuals. There is no specific treatment for
      West Nile Disease. The target population for a West Nile vaccine is older people, as they are
      more susceptible to severe disease. This trial includes a dose-finding part with a placebo
      control in young healthy adults, followed by a placebo-controlled examination of the chosen
      dose in older healthy adults.

      Outcome measures include a comparison of adverse events between active treatment and placebo,
      a comparison of antibody and viremia measurements between dose levels and across age groups
      for the dose chosen for Part 2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Fourfold or Greater Post-vaccination Titers (Seroconversion).</measure>
    <time_frame>Day 28 post-vaccination</time_frame>
    <description>Seroconversion was defined as a fourfold or greater rise in titer between pre- and post-immunization samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Viremic Participants Post-vaccination</measure>
    <time_frame>Day 21 post-vaccination</time_frame>
    <description>Viremic = detectable level of ≥ 10 plaque-forming units (PFU)/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-emergent Adverse Events Reported As Related to Study Treatment in at Least 5% of Participants in Any Active Treatment Group Post-vaccination.</measure>
    <time_frame>Days 0 to 28 post-vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Neutralizing Antibody Titers Pre- and Post-vaccination.</measure>
    <time_frame>Days 0, 14, and 28 post-vaccination</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Positive Immunoglobulin M (IgM) Response Post-vaccination in the As Treat Per-Protocol Population</measure>
    <time_frame>Days 14 and 28 post-vaccination</time_frame>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">208</enrollment>
  <condition>West Nile Fever</condition>
  <arm_group>
    <arm_group_label>Group 1: WN02 Low Dose (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Dose in healthy adults in Part 1 against a placebo control.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: WN02 Medium Dose (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium dose level in part one healthy subjects against a placebo control.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: WN02 High Dose (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose level in part one healthy subjects against a placebo control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: Placebo (Part 1)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single dose of saline in Part 1 on Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: WNO2 High Dose (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants enrolled in Part 2 and received a single dose of West Nile Virus vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6: Placebo (part 2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single dose of saline in Part 2 on Day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ChimeriVax-WN02 Low Dose</intervention_name>
    <description>Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region.</description>
    <arm_group_label>Group 1: WN02 Low Dose (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ChimeriVax-WN02 Medium Dose</intervention_name>
    <description>Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region</description>
    <arm_group_label>Group 2: WN02 Medium Dose (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ChimeriVax-WN02 High Dose</intervention_name>
    <description>Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region</description>
    <arm_group_label>Group 3: WN02 High Dose (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>0.9% Saline solution</intervention_name>
    <description>Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region</description>
    <arm_group_label>Group 4: Placebo (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ChimeriVax-WN02 High Dose</intervention_name>
    <description>Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region</description>
    <arm_group_label>Group 5: WNO2 High Dose (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>0.9 % NaCl solution</intervention_name>
    <description>Single dose given in a volume of 0.5 mL by subcutaneous injection to the deltoid region</description>
    <arm_group_label>Group 6: Placebo (part 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Part 1

          -  Healthy adult aged 18 to 40 years.

          -  Women of child-bearing potential should be using hormonal contraception.

          -  Subject had to be available for the study duration, including all planned follow-up
             visits.

        Exclusion Criteria: Part 1

          -  Previous vaccination against yellow fever or Japanese encephalitis

          -  History of flavivirus infection

          -  Any abnormalities of immune system, or using drugs that affect the immune system.

          -  History of anaphylaxis to foods, bee stings, vaccines or drugs.

          -  Receipt of blood or blood products within the preceding 6 months.

          -  Receipt of any vaccine in the preceding 30 days

          -  Seropositive to hepatitis C virus (HCV), hepatitis B surface antigen (HBsAg) or Human
             immunodeficiency virus (HIV)

          -  Lactation or intended pregnancy in female subjects

          -  Previous or current military service with overseas deployment

          -  Travel to Mexico or other flavivirus endemic areas in the tropics for periods of four
             weeks or more in the previous ten years.

        Inclusion Criteria: Part 2

          -  Aged ≥ 41 years.

          -  Subjects had to be in general good health.

          -  Unimpaired cognitive performance as assessed by clock drawing test score

          -  Subject had to be available for all required study visits, including all planned
             follow-up visits.

          -  Women of child-bearing potential should be using hormonal contraception.

        Exclusion Criteria: Part 2

          -  Clinically significant abnormalities on the Screening 12-lead electrocardiogram (ECG).

          -  An acute or chronic medical condition that, in the opinion of the Investigator, would
             render vaccination unsafe or would interfere with the evaluation of responses. These
             conditions included, but were not limited to:

               -  History of renal impairment

               -  History of significant liver disease or hepatic impairment

               -  History of diabetes mellitus (except controlled with diet)

               -  An arteriosclerotic event during the 6 months prior to enrollment (including but
                  not limited to myocardial infarction or unstable angina, peripheral bypass
                  surgery for revascularization of an extremity, and transient ischemic attack or
                  stroke)

               -  Signs of congestive heart failure at the time of enrollment

               -  Angina

          -  Subjects with 3 or more of the following:

               -  Age over 50 years

               -  Hypercholesterolemia, or significantly abnormal lipid profile, based on medical
                  history

               -  Any prior history of cardiovascular disease

               -  Significant family history of cardiovascular disease in any immediate relative

               -  History of significant collagen vascular disease.

          -  The unexplained presence of any of the following findings:

               -  Any significant episodes of confusion, memory loss, language impairment, other
                  cognitive impairment, or other abnormal behavior if relatively abrupt in onset

               -  Clinically significant depression

               -  Sudden visual impairment (e.g., loss of vision, double vision)

               -  Slurred or abnormal speech

               -  Sudden onset of vertigo

               -  Focal weakness in any extremity

               -  Focal sensory loss in any extremity

               -  Impaired balance

               -  Impaired gait.

          -  Subjects with any diagnosis of dementia or associated concomitant medications (e.g.,
             Aricept) used for treating dementia.

          -  Subjects with active or a history of neurologic disease or injury, including, but not
             limited to: Parkinson's, Guillain Barre, epilepsy (except febrile seizures in youth
             not treated with medication), cerebrovascular accident, head trauma, or any other
             neurologic condition thought to impact the integrity of the blood-brain barrier.

          -  Subjects taking warfarin, heparin, or with known bleeding disorders.

          -  Relative or employee of the study site staff, CRO, or Sponsor participating in this
             trial.

          -  A history of vaccination against yellow fever (YF) or Japanese encephalitis. Previous
             vaccination was determined by history (interview of subject) and/or by reviewing the
             subject's vaccination card or other official documentation.

          -  History of flavivirus infection (e.g. West Nile [WN], Systemic Lupus Erythematosus
             [SLE], Japanese encephalitis, dengue fever).

          -  History of thymoma, thymic surgery (removal), or myasthenia gravis.

          -  Known or suspected immunodeficiency disorder, including leukemia, lymphoma,
             generalized malignancy, or treatment with immunosuppressive medications, including
             corticosteroids, alkylating agents, anti-metabolites, or radiation therapy. Low dose
             steroids (≤ 10 mg prednisone or equivalent, topical or intra
             articular/bursal/tendon/epidural injections of corticosteroids) did not constitute a
             reason for exclusion.

          -  History of residence in or travel to Mexico or flavivirus endemic areas in the tropics
             (India, southeast Asia, Central America, Caribbean, or South America) for periods of 4
             weeks or more within the last 10 years.

          -  Subjects with clinically significant screening laboratory abnormalities and/or those
             having any of the following:

               -  Compromised hematopoietic function defined as a hemoglobin &lt; 10.9 (males) or 9.4
                  (females) g/dL; lymphocyte count &gt; 3000 mm3; neutrophil count &lt; 1000 mm3; or
                  platelet count &lt; 100,000 mm3.

               -  Hepatic dysfunction defined as a bilirubin above upper limit of normal or
                  aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 2 x upper
                  limit of normal.

          -  Prior history of anaphylaxis to foods, hymenoptera stings, vaccines, or drugs.

          -  Transfusion of blood or treatment with any blood product, including intramuscular or
             intravenous serum globulin within 6 months of the Screening Visit or anticipated up to
             Day 28, or intention to donate blood in the 28 days after vaccination.

          -  Administration of another vaccine within 30 days preceding the screening visit or
             anticipated up to Day 28 (these subjects could be rescheduled for vaccination at a
             later date).

          -  Physical examination indicating any clinically significant medical condition.

          -  Subjects with body temperature &gt;37.8ºC/100.0ºF or acute illness within 3 days prior to
             vaccination (subject could be rescheduled).

          -  Intention to travel out of the area prior to the study visit on Day 28, such that
             required study visits would be missed.

          -  Seropositive to HCV or HIV or positive for HBsAg.

          -  Participation in another clinical trial within 60 days of Screening.

          -  Lactation or intended pregnancy in female subjects.

          -  History of excessive alcohol consumption, drug abuse, or significant psychiatric
             illness.

          -  Intention to increase normal exercise routine, participate in contact sports or
             strenuous weight lifting, or to initiate vigorous exercise from Screening until after
             Day 28.

          -  At the time of study or past military service with overseas deployment within 10 years
             of screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HOPE Research Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Idaho Infectious Diseases, PLLC</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRA International Clinical Pharmacology Center</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bio-Kinetic Clinical Applications, Inc.</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Glennan Centre for Geriatrics and Gerontologyy, EVMS</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2007</study_first_submitted>
  <study_first_submitted_qc>February 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2007</study_first_posted>
  <results_first_submitted>January 21, 2011</results_first_submitted>
  <results_first_submitted_qc>January 21, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 14, 2011</results_first_posted>
  <last_update_submitted>April 12, 2016</last_update_submitted>
  <last_update_submitted_qc>April 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>West Nile Disease</keyword>
  <keyword>Antibody response</keyword>
  <keyword>Viremia</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>West Nile Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 09 December 2005 to 27 March 2006 in 5 clinical centers in the US.</recruitment_details>
      <pre_assignment_details>A total of 208 participants (Part 1 = 112; Part 2 = 96) who met the inclusion and exclusion criteria were enrolled, randomized, and vaccinated in the study. Report on Part 1 and Part 2 participants with valid data are presented in this report.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo (Part 1)</title>
          <description>Participants in Part 1 of the study who received a single dose of saline on Day 0</description>
        </group>
        <group group_id="P2">
          <title>WN02 Low Dose (Part 1)</title>
          <description>Participants in Part 1 of the study who received a single dose of West Nile Virus vaccine WN02, 3700 plaque-forming units, on Day 0</description>
        </group>
        <group group_id="P3">
          <title>WN02 Medium Dose (Part 1)</title>
          <description>Participants in Part 1 of the study who received a single dose of West Nile Virus vaccine WN02, 37000 plaque-forming units, on Day 0</description>
        </group>
        <group group_id="P4">
          <title>WN02 High Dose (Part 1)</title>
          <description>Participants in Part 1 of the study who received a single dose of West Nile Virus vaccine WN02, 37000 plaque-forming units, on Day 0</description>
        </group>
        <group group_id="P5">
          <title>Placebo (Part 2)</title>
          <description>Participants in Part 2 of the study who received a placebo vaccine on Day 0</description>
        </group>
        <group group_id="P6">
          <title>WNO2 High Dose (Part 2)</title>
          <description>Participants in Part 2 of the study who received a single dose of West Nile Virus vaccine WN02, 37000 plaque-forming units, on Day 0</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="31"/>
                <participants group_id="P5" count="0">Participants in Part 2 are not the same as those in Part 1</participants>
                <participants group_id="P6" count="0">Participants in Part 2 are not the same as those in Part 1</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="31"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Participants in Part 1 are not the same as those in Part 2</participants>
                <participants group_id="P2" count="0">Participants in Part 1 are not the same as those in Part 2</participants>
                <participants group_id="P3" count="0">Participants in Part 1 are not the same as those in Part 2</participants>
                <participants group_id="P4" count="0">Participants in Part 1 are not the same as those in Part 2</participants>
                <participants group_id="P5" count="25"/>
                <participants group_id="P6" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="25"/>
                <participants group_id="P6" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo (Part 1)</title>
          <description>Participants in Part 1 of the study who received a single dose of saline on Day 0</description>
        </group>
        <group group_id="B2">
          <title>WN02 Low Dose (Part 1)</title>
          <description>Participants in Part 1 of the study who received a single dose of West Nile Virus vaccine WN02, 3700 plaque-forming units, on Day 0</description>
        </group>
        <group group_id="B3">
          <title>WN02 Medium Dose (Part 1)</title>
          <description>Participants in Part 1 of the study who received a single dose of West Nile Virus vaccine WN02, 37000 plaque-forming units, on Day 0</description>
        </group>
        <group group_id="B4">
          <title>WN02 High Dose (Part 1)</title>
          <description>Participants in Part 1 of the study who received a single dose of West Nile Virus vaccine WN02, 37000 plaque-forming units, on Day 0</description>
        </group>
        <group group_id="B5">
          <title>Placebo (Part 2)</title>
          <description>Participants in Part 2 of the study who received a placebo vaccine on Day 0</description>
        </group>
        <group group_id="B6">
          <title>WNO2 High Dose (Part 2)</title>
          <description>Participants in Part 2 of the study who received a single dose of West Nile Virus vaccine WN02, 37000 plaque-forming units, on Day 0</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="31"/>
            <count group_id="B5" value="25"/>
            <count group_id="B6" value="57"/>
            <count group_id="B7" value="194"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="28"/>
                    <measurement group_id="B7" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.6" spread="6.41"/>
                    <measurement group_id="B2" value="25.4" spread="5.62"/>
                    <measurement group_id="B3" value="25" spread="5.43"/>
                    <measurement group_id="B4" value="25.1" spread="6.47"/>
                    <measurement group_id="B5" value="61.4" spread="11.8"/>
                    <measurement group_id="B6" value="61.0" spread="11.3"/>
                    <measurement group_id="B7" value="25.7" spread="6.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="40"/>
                    <measurement group_id="B7" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="57"/>
                    <measurement group_id="B7" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Fourfold or Greater Post-vaccination Titers (Seroconversion).</title>
        <description>Seroconversion was defined as a fourfold or greater rise in titer between pre- and post-immunization samples</description>
        <time_frame>Day 28 post-vaccination</time_frame>
        <population>Seroconversion was assessed in all participants in the safety population according to the vaccine actually received, As Treat Per-Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Part 1)</title>
            <description>Participants in Part 1 of the study who received a single dose of saline on Day 0</description>
          </group>
          <group group_id="O2">
            <title>WN02 Low Dose (Part 1)</title>
            <description>Participants in Part 1 of the study who received a single dose of West Nile Virus vaccine WN02, 3700 plaque-forming units, on Day 0</description>
          </group>
          <group group_id="O3">
            <title>WN02 Medium Dose (Part 1)</title>
            <description>Participants in Part 1 of the study who received a single dose of West Nile Virus vaccine WN02, 37000 plaque-forming units, on Day 0</description>
          </group>
          <group group_id="O4">
            <title>WN02 High Dose (Part 1)</title>
            <description>Participants in Part 1 of the study who received a single dose of West Nile Virus vaccine WN02, 37000 plaque-forming units, on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Placebo (Part 2)</title>
            <description>Participants in Part 2 of the study who received a placebo vaccine on Day 0</description>
          </group>
          <group group_id="O6">
            <title>WNO2 High Dose (Part 2)</title>
            <description>Participants in Part 2 of the study who received a single dose of West Nile Virus vaccine WN02, 37000 plaque-forming units, on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Fourfold or Greater Post-vaccination Titers (Seroconversion).</title>
          <description>Seroconversion was defined as a fourfold or greater rise in titer between pre- and post-immunization samples</description>
          <population>Seroconversion was assessed in all participants in the safety population according to the vaccine actually received, As Treat Per-Protocol Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Neutralizing Antibody Titers Pre- and Post-vaccination.</title>
        <time_frame>Days 0, 14, and 28 post-vaccination</time_frame>
        <population>Geometric mean titers were assessed according to the vaccine actually received, in the As treat per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Part 1)</title>
            <description>Participants in Part 1 of the study who received a single dose of saline on Day 0</description>
          </group>
          <group group_id="O2">
            <title>WN02 Low Dose (Part 1)</title>
            <description>Participants in Part 1 of the study who received a single dose of West Nile Virus vaccine WN02, 3700 plaque-forming units, on Day 0</description>
          </group>
          <group group_id="O3">
            <title>WN02 Medium Dose (Part 1)</title>
            <description>Participants in Part 1 of the study who received a single dose of West Nile Virus vaccine WN02, 37000 plaque-forming units, on Day 0</description>
          </group>
          <group group_id="O4">
            <title>WN02 High Dose (Part 1)</title>
            <description>Participants in Part 1 of the study who received a single dose of West Nile Virus vaccine WN02, 37000 plaque-forming units, on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Placebo (Part 2)</title>
            <description>Participants in Part 2 of the study who received a placebo vaccine on Day 0</description>
          </group>
          <group group_id="O6">
            <title>WNO2 High Dose (Part 2)</title>
            <description>Participants in Part 2 of the study who received a single dose of West Nile Virus vaccine WN02, 37000 plaque-forming units, on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Neutralizing Antibody Titers Pre- and Post-vaccination.</title>
          <population>Geometric mean titers were assessed according to the vaccine actually received, in the As treat per-protocol population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O4" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O5" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O6" value="5" lower_limit="5.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="16.8" lower_limit="7.2" upper_limit="39.5"/>
                    <measurement group_id="O3" value="35.7" lower_limit="18.3" upper_limit="69.7"/>
                    <measurement group_id="O4" value="26.9" lower_limit="11.8" upper_limit="61.5"/>
                    <measurement group_id="O5" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O6" value="19.2" lower_limit="11.9" upper_limit="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="1367.3" lower_limit="711.3" upper_limit="2628.5"/>
                    <measurement group_id="O3" value="2331.1" lower_limit="1193.3" upper_limit="4554.3"/>
                    <measurement group_id="O4" value="3309.3" lower_limit="1726.9" upper_limit="6341.7"/>
                    <measurement group_id="O5" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O6" value="922.4" lower_limit="519.2" upper_limit="1638.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Positive Immunoglobulin M (IgM) Response Post-vaccination in the As Treat Per-Protocol Population</title>
        <time_frame>Days 14 and 28 post-vaccination</time_frame>
        <population>Immunoglobulin M (IgM) response was assessed in all participants in the safety population according to the vaccine actually received, As Treat Per-Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Part 1)</title>
            <description>Participants in Part 1 of the study who received a single dose of saline on Day 0</description>
          </group>
          <group group_id="O2">
            <title>WN02 Low Dose (Part 1)</title>
            <description>Participants in Part 1 of the study who received a single dose of West Nile Virus vaccine WN02, 3700 plaque-forming units, on Day 0</description>
          </group>
          <group group_id="O3">
            <title>WN02 Medium Dose (Part 1)</title>
            <description>Participants in Part 1 of the study who received a single dose of West Nile Virus vaccine WN02, 37000 plaque-forming units, on Day 0</description>
          </group>
          <group group_id="O4">
            <title>WN02 High Dose (Part 1)</title>
            <description>Participants in Part 1 of the study who received a single dose of West Nile Virus vaccine WN02, 37000 plaque-forming units, on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Placebo (Part 2)</title>
            <description>Participants in Part 2 of the study who received a placebo vaccine on Day 0</description>
          </group>
          <group group_id="O6">
            <title>WNO2 High Dose (Part 2)</title>
            <description>Participants in Part 2 of the study who received a single dose of West Nile Virus vaccine WN02, 37000 plaque-forming units, on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive Immunoglobulin M (IgM) Response Post-vaccination in the As Treat Per-Protocol Population</title>
          <population>Immunoglobulin M (IgM) response was assessed in all participants in the safety population according to the vaccine actually received, As Treat Per-Protocol Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IgM Positive at Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM Positive at Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Viremic Participants Post-vaccination</title>
        <description>Viremic = detectable level of ≥ 10 plaque-forming units (PFU)/mL</description>
        <time_frame>Day 21 post-vaccination</time_frame>
        <population>Viremia was assessed in all participants in the safety population according to the vaccine actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Part 1)</title>
            <description>Participants in Part 1 of the study who received a single dose of saline on Day 0</description>
          </group>
          <group group_id="O2">
            <title>WN02 Low Dose (Part 1)</title>
            <description>Participants in Part 1 of the study who received a single dose of West Nile Virus vaccine WN02, 3700 plaque-forming units, on Day 0</description>
          </group>
          <group group_id="O3">
            <title>WN02 Medium Dose (Part 1)</title>
            <description>Participants in Part 1 of the study who received a single dose of West Nile Virus vaccine WN02, 37000 plaque-forming units, on Day 0</description>
          </group>
          <group group_id="O4">
            <title>WN02 High Dose (Part 1)</title>
            <description>Participants in Part 1 of the study who received a single dose of West Nile Virus vaccine WN02, 37000 plaque-forming units, on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Placebo (Part 2)</title>
            <description>Participants in Part 2 of the study who received a placebo vaccine on Day 0</description>
          </group>
          <group group_id="O6">
            <title>WNO2 High Dose (Part 2)</title>
            <description>Participants in Part 2 of the study who received a single dose of West Nile Virus vaccine WN02, 37000 plaque-forming units, on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Viremic Participants Post-vaccination</title>
          <description>Viremic = detectable level of ≥ 10 plaque-forming units (PFU)/mL</description>
          <population>Viremia was assessed in all participants in the safety population according to the vaccine actually received.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Treatment-emergent Adverse Events Reported As Related to Study Treatment in at Least 5% of Participants in Any Active Treatment Group Post-vaccination.</title>
        <time_frame>Days 0 to 28 post-vaccination</time_frame>
        <population>Safety analysis was on all enrolled and vaccinated participants according to the vaccine actually received, safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Part 1)</title>
            <description>Participants in Part 1 of the study who received a single dose of saline on Day 0</description>
          </group>
          <group group_id="O2">
            <title>WN02 Low Dose (Part 1)</title>
            <description>Participants in Part 1 of the study who received a single dose of West Nile Virus vaccine WN02, 3700 plaque-forming units, on Day 0</description>
          </group>
          <group group_id="O3">
            <title>WN02 Medium Dose (Part 1)</title>
            <description>Participants in Part 1 of the study who received a single dose of West Nile Virus vaccine WN02, 37000 plaque-forming units, on Day 0</description>
          </group>
          <group group_id="O4">
            <title>WN02 High Dose (Part 1)</title>
            <description>Participants in Part 1 of the study who received a single dose of West Nile Virus vaccine WN02, 37000 plaque-forming units, on Day 0</description>
          </group>
          <group group_id="O5">
            <title>Placebo (Part 2)</title>
            <description>Participants in Part 2 of the study who received a placebo vaccine on Day 0</description>
          </group>
          <group group_id="O6">
            <title>WNO2 High Dose (Part 2)</title>
            <description>Participants in Part 2 of the study who received a single dose of West Nile Virus vaccine WN02, 37000 plaque-forming units, on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-emergent Adverse Events Reported As Related to Study Treatment in at Least 5% of Participants in Any Active Treatment Group Post-vaccination.</title>
          <population>Safety analysis was on all enrolled and vaccinated participants according to the vaccine actually received, safety population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling Hot</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somnolence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal stiffness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pharyngolaryngeal pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not collected in Part 1</measurement>
                    <measurement group_id="O2" value="NA">Not collected in Part 1</measurement>
                    <measurement group_id="O3" value="NA">Not collected in Part 1</measurement>
                    <measurement group_id="O4" value="NA">Not collected in Part 1</measurement>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not collected in Part 1</measurement>
                    <measurement group_id="O2" value="NA">Not collected in Part 1</measurement>
                    <measurement group_id="O3" value="NA">Not collected in Part 1</measurement>
                    <measurement group_id="O4" value="NA">Not collected in Part 1</measurement>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from the day of vaccination to up to 6 months, post-vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo (Part 1)</title>
          <description>Participants in Part 1 of the study who received a single dose of saline on Day 0</description>
        </group>
        <group group_id="E2">
          <title>WN02 Low Dose (Part 1)</title>
          <description>Participants in Part 1 of the study who received a single dose of West Nile Virus vaccine WN02, 3700 plaque-forming units, on Day 0</description>
        </group>
        <group group_id="E3">
          <title>WN02 Medium Dose (Part 1)</title>
          <description>Participants in Part 1 of the study who received a single dose of West Nile Virus vaccine WN02, 37000 plaque-forming units, on Day 0</description>
        </group>
        <group group_id="E4">
          <title>WN02 High Dose (Part 1)</title>
          <description>Participants in Part 1 of the study who received a single dose of West Nile Virus vaccine WN02, 37000 plaque-forming units, on Day 0</description>
        </group>
        <group group_id="E5">
          <title>Placebo (Part 2)</title>
          <description>Participants in Part 2 of the study who received a placebo vaccine on Day 0</description>
        </group>
        <group group_id="E6">
          <title>WNO2 High Dose (Part 2)</title>
          <description>Participants in Part 2 of the study who received a single dose of West Nile Virus vaccine WN02, 37000 plaque-forming units, on Day 0</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 8.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia obstructive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive plumonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 8.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="54" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E6" events="14" subjects_affected="14" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Feeling Hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E6" events="14" subjects_affected="14" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E6" events="9" subjects_affected="9" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E6" events="11" subjects_affected="11" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E6" events="19" subjects_affected="19" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="17" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E5" events="9" subjects_affected="9" subjects_at_risk="32"/>
                <counts group_id="E6" events="18" subjects_affected="18" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

